Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide added to induction and maintenance therapy for newly diagnosed AML or high-risk MDS
NL-OMON55471Phase 3Completed
- Sponsor
- HOVON
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by HOVON. Primary endpoints: Lenalidomide dose level selection, Event-free survival and 1 more. Started Apr 2014; status: completed.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON55471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55471.